Clinical trials: Affective Disorder
Major Depressive Disorder
Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting
- Trial name
- LEAPS (NCT00479726)
- Testing
- duloxetine hydrochloride
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Bipolar Disorder
Relative Effectiveness of Schizophrenia Therapy Study
The purpose of this study is to validate that SULT4A1-1 status stratification improves responses to atypical antipsychotics in schizophrenia and to extend these findings into bipolar disorder.
- Trial name
- REST (NCT01245348)
- Testing
- SULT4A1-1 genetic test
- Where
- United States
- Volunteers
- 1,110 people
- Sponsor
- Medco Health Solutions, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD).
- Trial name
- NCT02431806
- Testing
- Levomilnacipran, Fluoxetine
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 552 people
- Sponsor
- Forest Laboratories
Depressive Disorder
Paxil CR Bioequivalence Study Brazil - Fed Administration
The study is prospective, open, randomized, crossover in steady state and the volunteers received multiple doses of the test drug and the reference drug (two periods of drug administration after standardized meals).
- Trial name
- NCT01339247
- Testing
- Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06423781
- Testing
- BHV-7000
- Where
- 66 sites in United States
- Volunteers
- 233 people
- Sponsor
- Biohaven Therapeutics Ltd.
Bipolar Disorder
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar…
- Trial name
- SMART-M (NCT00545675)
- Testing
- Abilify(aripiprazole), Depakote (divalproate)
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder (MDD
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
- Trial name
- NCT05416762
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Bipolar Disorder
9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00143182
- Testing
- Asenapine, Olanzapine
- Volunteers
- 504 people
- Sponsor
- Organon and Co
Bipolar Disorder, Mania
Safety and Efficacy of Cariprazine for Mania
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.
- Trial name
- NCT01058096
- Testing
- Cariprazine
- Where
- 28 sites in United States, India
- Volunteers
- 323 people
- Sponsor
- Forest Laboratories
Bipolar Disorder
Lamotrigine Phase III Study in Bipolar I Disorder
This registration study in China is a multi-centre, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of lamotrigine in the prevention of recurrence/relapse of mood episodes in subjects with…
- Trial name
- NCT01602510
- Testing
- Lamotrigine
- Where
- 21 sites in China
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01944969
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
Study of Aripiprazole in Patients With Acute Bipolar Mania
The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
- Trial name
- NCT00097266
- Testing
- Aripiprazole, Haloperidol
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
Trazodone Once a Day in Major Depression Disorder
The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.
- Trial name
- NCT02086929
- Testing
- Trazodone, Venlafaxine
- Where
- 32 sites in Austria, Czechia and 4 more
- Volunteers
- 364 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.